# High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Source: https://onco.cc/trials/nct04221035/  
OnCo record `nct04221035` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Vincristine, Carboplatin, Etoposide, Vindesine, Dacarbazine, Ifosfamide, Doxorubicin, Busulfan, Melphalan, Thiotepa, Dinutuximab, Cisplatin and Irinotecan in High-risk neuroblastoma, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.

## Summary

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) is a phase 3 interventional study registered as NCT04221035 by Gustave Roussy, Cancer Campus, Grand Paris, with 800 participants planned, started 2019-11-05 and due to reach its primary completion in 2026-11. Interventions recorded: Vincristine, Carboplatin, Etoposide, Vindesine, Dacarbazine, Ifosfamide, Doxorubicin, Busulfan, Melphalan, Thiotepa, Radiotherapy, Dinutuximab Beta, Cisplatin, Temozolomide 100 MG, Irinotecan, Cyclophosphamid. Conditions recorded: High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy.

Linked to the drug Vindesine because the registry names it among its interventions and High-risk neuroblastoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04221035
- Phase: 3
- Setting: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
- Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- Enrolled: 800

## Sources

- ClinicalTrials.gov NCT04221035: https://clinicaltrials.gov/study/NCT04221035

## Connected records

- cancers: [High-risk neuroblastoma](https://onco.cc/cancers/neuroblastoma-high-risk/)
- drugs: [Busulfan](https://onco.cc/drugs/busulfan/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Dacarbazine](https://onco.cc/drugs/dacarbazine/), [Dinutuximab (ch14.18) / dinutuximab beta](https://onco.cc/drugs/dinutuximab/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Etoposide](https://onco.cc/drugs/etoposide/), [Ifosfamide](https://onco.cc/drugs/ifosfamide/), [Irinotecan (and liposomal irinotecan)](https://onco.cc/drugs/irinotecan/), [Melphalan (including hepatic delivery system)](https://onco.cc/drugs/melphalan/), [Thiotepa](https://onco.cc/drugs/thiotepa/), [Vincristine](https://onco.cc/drugs/vincristine/), [Vindesine](https://onco.cc/drugs/vindesine/)

---
JSON: https://onco.cc/api/v1/entities/nct04221035.json